Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
Study Identifier
191622-120
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Statistical Analysis Plan
Available Language(s): English
Protocol
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 3
Sex
Female & Male
Age
5 - 17 Years
Protocol Summary
This study will evaluate the 3 doses of onabotulinumtoxinA (botulinum toxin Type A) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in pediatric participants between the ages of 5 to 17 years to determine if 1 or more doses were safe and effective.
Study Locations
Location
Status
Location
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Status
Not applicable
Location
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Status
Not applicable
Location
Children's Hospital of Orange County
Orange, California, United States, 92868
Status
Not applicable
Location
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
Status
Not applicable
Location
Riley Hospital for Children
Indianapolis, Indiana, United States, 46032
Status
Not applicable
Location
William Beaumont Hospital Research Institute
Royal Oak, Michigan, United States, 48073
Status
Not applicable
Showing {first} - {last} of {total} Results